Hikma Pharmaceuticals

for and . is delighted to announce that this morning it completed Xellia’s acquisition. Dr Bill Larkins, President, Injectables said that this acquisition adds significant scale to Hikma’s US operations and enhances our injectable manufacturing capabilities and portfolio by adding complex technologies. I am confident that this transaction will deliver significant future value to Hikma’s Injectables business, supporting growth over the medium term.

Read our press release https://www.hikma.com/news/hikma-completes-xellia-acquisition/

Meet Osama Alrifai, Quality Assurance Manager at Hikma Jordan, and discover how he champions quality to put better health within reach, every day at
Learn more: https://www.hikma.com/

Meet Daniel Miller, Senior Specialist, Regulatory Intelligence and Compliance Training at Hikma US, and discover how he champions quality to put better health within reach, every day at

Learn more: https://www.hikma.com/

for and . delivers a strong first 2024 half year performance.

Read the press release herehttps://www.hikma.com/media/ul4ifnxb/2024-interim-press-release-vfinal-combined.pdf

for and .

Listen to Khalid Nabilsi, Hikma’s CFO, talk about Hikma’s strong H1 2024 performance, delivering revenue growth in each of our three businesses and upgrading our full-year Group guidance today.

See video here: https://youtu.be/f-xfpkLqbSQ?si=3WD2QWfTodXBaczD

Read the press release here:https://www.hikma.com/media/ul4ifnxb/2024-interim-press-release-vfinal-combined.pdf

Khalid Nabilsi, CFO, 2024 Interim Results. 8 August 2024 Khalid Nabilsi, CFO, 2024 Interim Results. 8 August 2024www.hikma.com

for and . delivers strong H1 2024 performance and upgrades Group guidance

Watch Riad Mishlawi, Hikma’s Chief Executive Officer discuss our excellent first half performance
✔️ All of our businesses contributed to our strong performance, delivering 10% Group revenue growth
✔️ We launched new products across all regions, entered new markets in Europe, and further strengthened our leadership team.
✔️ Our Branded business performed extremely well, benefitting from the ongoing investment in growing our portfolio of oncology and chronic treatments
✔️ Injectables is maintaining good momentum, with new launches and recently added capacity driving growth, while our strategic acquisition of Xellia’s products, manufacturing facility and R&D assets, once closed, will support the long-term prospects of this business
✔️ Generics continues to differentiate through our focus on more complex products and the quality of our US-based manufacturing capabilities
✔️ We are pleased to upgrade Group revenue and profit guidance
✔️ We have a fantastic team of talented people, without whom this performance would not have been possible.

https://youtu.be/miwyJgv2GLc

Read the press release herehttps://www.hikma.com/media/ul4ifnxb/2024-interim-press-release-vfinal-combined.pdf

Riad Mishlawi, Chief Executive Officer, 2024 Interim Results, 8 August 2024 Riad Mishlawi, Chief Executive Officer of Hikma - 2024 Interim Results. 8 August 2024, 07:00 AM GMT+1.www.hikma.com

We are delighted that our Executive Chairman, Said Darwazah, has been named in the Arabian Business Healthcare Visionaries List 2024. Since our founding, Hikma has been dedicated to reliably supplying customers with vital and life-saving medications. We have never strayed from this mission, and our 9,100 employees are proud to be guided by this purpose. We continue to push boundaries in putting , , .

ArabianBusiness

On , reaffirms its commitment to advancing . As a leading provider of oncology medicine in MENA, we are dedicated to innovation, raising awareness, and delivering accessible, high-quality treatments. Through our strategic partnerships, our strong regional presence and global expertise to introduce cutting-edge technologies, we are playing an important part in improving cancer care in the region.

At Hikma, we improve lives and make impact by providing broad access to hundreds of affordable, high-quality medicines across North America, the Middle East, North Africa, and Europe. Our Medicine Donations Programme, which has grown 53% since 2021 to $4.9 million in 2023, supports patients with chronic conditions as well as marginalised populations through streamlined partnerships with global NGOs to offer donations of medicines and medical equipment.



Learn more about how we’re enhancing global access: https://www.hikma.com/responsibility/acting-responsibly/advancing-health-and-wellbeing/

Meet Mariam Mukarker, Manager, Quality, MENA, and discover why she likes working at ! Watch the video.
https://youtu.be/f4t9MZxztZI

Learn more https://www.hikma.com/responsibility/acting-responsibly/empowering-our-people/

#OwnYourCareer | Mariam Mukarker, Manager, Quality, MENA | Mariam Mukarker, Manager, Quality, MENA and discover why she likes working at ! Learn mo...

Today, we're celebrating National Intern Day at !

Our interns are an important part of our team, bringing fresh perspectives and enthusiasm to our work. We're proud to provide valuable experiences that help shape the future leaders of our industry.

Hear from some of our talented interns as they share their experiences at Hikma.

Our people drive our impact. We empower them through a culture of progress and belonging that enables them to thrive. We continue to focus on retaining and recruiting high-calibre talent, enhancing the skills and potential of our employees, and taking steps to promote diversity, equity and inclusion. Our recent Hikma’s People Voice Survey assessed employee sentiment on various issues, guiding us in enhancing the employee experience at Hikma.

To read more about life at Hikma: https://www.hikma.com/careers/why-hikma/

At Hikma, we use our global footprint and diverse portfolio to make a significant impact with affordable, high-quality medicines. As MENA's second-largest pharmaceutical company by sales [1], we continuously innovate to expand our reach, launching first-to-market generic products, in key therapeutic areas.

Learn more: https://www.hikma.com/who-we-are/purpose-strategy-and-culture/

[1] IQVIA MIDAS Pharma Index MAT Feb-2024. Retail + Hospital. Excluding Milks and diagnostics. Excluding Lebanon.

Meet Beatrice Mazza, Regulatory Affairs Officer at Hikma Italy, and discover how she champions quality to put better health within reach, every day at .
Learn more: https://www.hikma.com/

In 2023, we achieved a 15% reduction in our Scope 1 and 2 emissions compared to our 2020 baseline, saving 123,727 tonnes of CO2. We also enhanced water management and set targets to achieve good water stewardship across the MENA by 2025. Advancing our sustainability agenda allows us to continue making a positive impact towards patients, people, planet and communities.
Learn more: https://www.hikma.com/responsibility/sustainability-reports/

for and . will announce its interim financial results for the six months ended 30 June 2024 on Thursday 8 August 2024.
A recording of the presentation will be available on the Group’s website at www.hikma.com from 7:00AM BST. Hikma will also hold a live Q&A conference call for analysts at 9:30AM BST, and a recording will be made available on the Company’s website.

For further information: https://www.hikma.com/news/notice-of-results-7/

Through our three business units - Injectables, Generics, and Branded - we deliver high-quality, affordable medicines across North America, MENA, and Europe. As a top-three US supplier of injectables [1] and the second-largest pharmaceutical company in MENA by sales [2], our extensive manufacturing capabilities and deep local expertise enable us to meet diverse healthcare needs, improving patient access to essential medicine.

Read more: https://www.hikma.com/what-we-do/our-businesses/

[1] IQVIA MAT April 2024, generic injectable volumes by eaches, excluding branded generics and Becton Dickinson)

[2] IQVIA MIDAS Pharma Index MAT Feb-2024. Retail + Hospital. Excluding Milks and diagnostics. Excluding Lebanon.

In 2023 we launched 157 new products, enhancing global access to affordable treatments, and reinforcing our purpose to put better health within reach, every day. Our continued investment in R&D and manufacturing capabilities strengthens our position as a leading supplier of generic injectable, non-injectable, specialty, and branded pharmaceutical products, and amplifies our positive impact on patient outcomes.

Find out more about our impact and performance:https://www.hikma.com/media/ex1jgvy1/hikma-2023-full-annual-report.pdf

Hikma is committed to advancing health and wellbeing by supporting local community healthcare initiatives and educational programmes. Recently, Hikma partnered with to modernise the summer art space at Camp Oty’Okwa in the Hocking Hills region. With Hikma’s grant, they purchased new art tables, chairs, storage cabinets, a Glowforge laser, and a smart cutting machine. The result is a beautiful new space for campers to explore their creativity and artistic expression.

Read more about how we’re supporting our communities: https://brnw.ch/21wL8Qi

Meet Malek Saleem, Manager Finance, Injectables, MENA, and discover why he likes working at ! Watch the video.
https://youtu.be/E4_Rb599kLU
Learn more: https://www.hikma.com/responsibility/acting-responsibly/empowering-our-people/

#OwnYourCareer | Malek Saleem, Manager Finance, Injectables, MENA | Malek Saleem, Manager Finance, Injectables, MENA and discover why he likes working at ! ...

For over 45 years, Hikma has been committed to putting better health within reach for patients. Our impact is clear:
• Providing access to more than 760 products across North America, MENA, and Europe
• Employing 9,100 people worldwide
• Continuous investment in R&D for future treatments
• Strong financial performance enabling expanded product development and manufacturing
• Active community involvement through local activities and medicine donations totalling $4.9M in value as of 2023.
Every day, we work to increase access to high-quality, affordable medicines. Our diverse portfolio of generic, specialty, and branded pharmaceuticals is making a real difference in patients' lives.

Learn more about our impact: https://www.hikma.com/who-we-are/impact/

Everyone deserves a chance to rebuild their life with dignity and hope. This , we celebrate refugees, their strength and resolve, and advocate for greater inclusion and opportunities for them to thrive in their new communities. is proud to support the scholarship programme, sponsoring 80 tertiary education scholarships for refugees and helping them to build a brighter future.

one blood donation can save up to 3 lives! [1] Every donation is precious and has the potential to make a real difference.

At , we believe every blood donation is a gift of life. This year, in honour of , our incredible Hikma blood donors came together during our blood donation drives, making a significant impact in communities across the MENA region.

In 2023 alone, Hikma's blood donors contributed over 425 litres, helping to address critical blood shortages. We are incredibly proud of our for their compassion and commitment to giving back!



[1] https://www.who.int/westernpacific/news/item/11-06-2015-a-gift-that-saves-lives-who-calls-on-everyone-to-regularly-give-blood

Meet Maya Beano, Manager, Pipeline Selection, Injectables, MENA, and discover why she likes working at ! Watch the video.

https://youtu.be/Y9fXCiPn6n0
Learn more: https://www.hikma.com/.../acting.../empowering-our-people/

#OwnYourCareer | Maya Beano, Manager, Pipeline Selection, Injectables, MENA | Maya Beano, Manager, Pipeline Selection, Injectables, MENA and discover why she likes working at ! ...

Today is , and we are proud to reaffirm our commitment to protecting the environment. We are actively working towards a 25% reduction in carbon emissions (Scope 1 and 2) by 2030, relative to our 2020 levels, and a key part of this includes investing in solar energy. Our central warehouse facility in Saudi Arabia has been utilising solar power to significantly decrease our carbon footprint. Since October 2023, this has resulted in estimated savings of 100 tons of CO₂* emissions, with an estimated saving of 10,936 tons of CO₂* over the next 30 years.

Read more about how we’re protecting the environment: https://www.hikma.com/responsibility/sustainability-reports/

*Data from Huawei FusionSolar system, Hikma Saudi Arabia Central Warehouse.

https://youtu.be/3SD_Tb4YYSM?si=tANlM63C6sUecENu

Hikma Saudi Arabia | Protecting the environment We are proud to reaffirm our commitment to protecting the environment. We are actively working towards a 25% reduction in carbon emissions (Scope 1 and 2) by...

for and . opens a new UK office to support NHS supply, strengthening its European presence.
Read the press release here: https://brnw.ch/21wKnwz

At , supporting local green initiatives is an important part of our commitment to protecting the environment. Recently, our in refreshed local garden boxes, planting vegetables, flowers, and local species for the third consecutive year. In , our team assisted Cleveland Metroparks in restoring a picnic area, and in , they volunteered to restore a wetland at the Great Swamp Wildlife Refuge, removing invasive species to create a more hospitable habitat for wildlife like birds, foxes, and owls. Together, our efforts help to keep our local communities thriving.

Learn more https://www.hikma.com/responsibility/acting-responsibly/protecting-the-environment/

On , Hikma proudly stands with the MS community, inspired by their resilience and strength. As a leading provider of MS treatments in the , our commitment to improving access aligns with our values as we remain dedicated to supporting the needs of patients and improving outcomes, to put better health within reach, every day.

Our Sustainability team continues to engage employees across departments and continents, inspiring more sustainable practices. Teams from Procurement, Operations, HR, R&D in , and our HQ in have participated in sessions deepening their understanding of climate science. As we continue to integrate sustainability into our operations, we remain focused on our goal of 25% emissions reduction by 2030. Every action counts as we strive to make a positive impact in protecting our environment.

Read more about how we’re acting responsibly: https://www.hikma.com/responsibility/sustainability-reports/

Last week, hosted the 3rd MENA Biotech Forum at the Dead Sea, Jordan, bringing together leading healthcare professionals who shared and discussed the latest advancements in , , and .
As the second largest pharmaceutical company in by sales[1], we strive to ensure we consistently provide essential medicines to patients. Contributing positively to society remains our purpose.

[1] IQVIA MIDAS Pharma Index MAT Feb-2024. Retail + Hospital. Excluding Milks and diagnostics. Excluding Lebanon

Learn more: https://www.hikma.com/